TITLE

FDA Approves AVONEX(r) PEN(tm) and Dose Titration Regimen

PUB. DATE
February 2012
SOURCE
Biomedical Market Newsletter;2/28/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article provides information on an announcement made by Biogen Idec Inc., regarding the approval of its drug AVONEX (®) PEN (™) and Dose Titration Regimen by the U.S. Food and Drug Administration. AVONEX PEN is the first intramuscular (IM) autoinjector approved for the treatment of multiple sclerosis. The new dose titration regimen is used to gradually escalating the dose of AVONEX at treatment initiation to reduce the incidence and severity of flu-like symptoms.
ACCESSION #
75290052

 

Related Articles

  • Acorda/Biogen Idec: pricing will determine success of symptomatic MS therapy.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p10 

    The article reports on the approval of Ampyra from Acorda Therapeutics Inc. and Biogen Idec Inc. for the symptomatic treatment of multiple sclerosis by the U.S. Food and Drug Administration (FDA). It is said that the treatment is the first symptomatic option to be approved by the FDA for...

  • Biogen Idec, Elan Release Antegren Results for Approval.  // Chemical Market Reporter;11/15/2004, Vol. 266 Issue 17, p14 

    Reports on the release of the results of a late-stage trial of Antegren or natalizumab, a multiple sclerosis treatment developed by Biogen IDEC and Elan Corp. PLC in November 2004. Preparation for the U.S. Food and Drug Administration's final review of the drug; Composition of the drug; Safety...

  • New Treatment for Multiple Sclerosis.  // FDA Consumer;Jan/Feb2005, Vol. 39 Issue 1, p6 

    Reports on a license given by the U.S. Food and Drug Authority to the Tysabri monoclonal antibody manufactured by Biogen Idec Inc. in 2004. Use of the drug in treating multiple sclerosis; Administration of the drug; Information on monoclonal antibodies; Function of Tysabri; Results of a...

  • MS Drug Back on Market Under Restricted Program.  // FDA Consumer;Jul/Aug2006, Vol. 40 Issue 4, p7 

    The article reports on an application to resume the marketing of Tysabri (natalizumab) approved by the U.S. Food and Drug Administration (FDA) under a special restricted distribution program. Tysabri is a drug used to treat people with relapsing forms of multiple sclerosis to reduce the...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Feb2011, Vol. 10 Issue 2, p4 

    The article provides updates on the development of drugs for multiple sclerosis. A complete response letter from the U.S. Food and Drug Administration (FDA) has been received by Teva Pharmaceutical Industries Ltd. for its supplemental New Drug Application (sNDA). Applications to update Tysabri...

  • Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article provides information on an announcement made by Biogen Idec Inc., regarding its submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of BG-12, an oral therapeutic candidate for the treatment of multiple sclerosis (MS). The drug...

  • FDA Approvals In March.  // BioWorld Insight;4/15/2013, Vol. 21 Issue 16, p7 

    A table is presented which lists several drugs approved by the U.S. Food and Drug Administration along with their companies including Biogen Idec Inc, Cangene Corp and Genentech Inc.

  • Gilenya.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article reports on U.S. Food and Drug Administration's (FDA) approval of the use of Gilenya capsules (fingolimod) to reduce relapses and delay progressive disability in patients with multiple sclerosis (MS).

  • New Drug Approved for Multiple Sclerosis.  // Clarendon Enterprise (TX);10/18/2012, Vol. 23 Issue 42, p4 

    The article informs that the U.S. Food and Drug Administration has approved the new drug Aubagio for the treatment of Multiple Sclerosis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics